NT-proBNP measurements in high-risk diabetic patients - A case series from Mamelodi (Gauteng)

Cardiovascular Journal of South Africa

Volumn 17, Issue 2, 2006, Pages 56-59

  Deffur, A ^a   Ker, J A ^b   Rheeder, P ^a   Van Niekerk, M M ^c   Quinton, S J ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b STEVE BIKO ACADEMIC HOSPITAL   (South Africa)

^c Ampath Trust   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PREVALENCE; RISK ASSESSMENT; SOUTH AFRICA; SYSTOLIC BLOOD PRESSURE;

BIOLOGICAL MARKERS; BLOOD PRESSURE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; ODDS RATIO; PEPTIDE FRAGMENTS;

EID: 33745663311     PISSN: 10159657     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Maeda K, Tsutamota T, Wada A, et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998; 135: 825-832.
2. Krishnaswamy P, Lubien E, Clopton P, et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med 2001; 111: 274-279.
3. De Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362: 316-322.
4. Pfister R, Erdmann E, Schneider CA. Die natriuretischen Peptide BNP und NT-pro-BNP-die 'neuen Troponine' der Herzinsuffizienz? Dtsch Med Wochenschr 2003; 128: 1007-1012.
5. Ramachandran SV, Emelia JB, Martin GL, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction (The Framingham Heart Study). J Am Med Assoc 2002; 288: 1252-1259.
6. Struthers AD, Morris AD. Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet 2002; 359: 1430-1432.
7. Wang TJ, Levy D, Benjamin EJ, et al. The epidemiology of 'asymptomatic' left ventricular systolic dysfunction: implications for screening. Ann Intern Med 2003; 138: 907-916.
8. Butler RA, MacDonald TM, et al. The clinical implications of diabetic heart disease. Eur Heart J 1998; 9: 1617-1927.
9. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
10. Cowie MR, Jourdian, P, e.m. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J 2003; 24: 1710-1718.
11. Rose GA. Chest pain questionnaire. Milbank Mem Fund Q 1965; 43: 32-39.
12. Marantz PR, Tobin JN, Wassertheil-Smaller S, et al. The relationship between left ventricular systolic function and congestive heart failure diagnosed by clinical criteria. Circulation 1988; 77: 607-612.
13. Chobanian AV. The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. J Am Med Assoc 2003; 289: 2560.
14. American Thoracic Society. ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-117.
15. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974; 34: 29-34.
16. Epshteyn V, Morrison K, Krishnaswamy P, et al. Utility of B-type natriuretic peptiede (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabet Care 2003; 26: 2081-2087.